• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CRO Cetero seeks bankruptcy protection

CRO Cetero seeks bankruptcy protection

March 26, 2012
CenterWatch Staff

Cetero, a CRO based in Cary, N.C., has filed for bankruptcy just eight months after the FDA caught the company manipulating samples and faking documents, according to Reuters.

The misconduct discovery, made last July, originated from two FDA inspections of Cetero’s Houston facility in 2010, followed by an internal investigation and an audit from a third party. Cetero, as an early-phase research and bioanalysis company, may have given drugmakers faulty documents that were then used as supporting evidence in applications to the FDA for drug approval, according to Reuters. Due to the discovery, the FDA warned drugmakers that studies supported by Cetero between April 2005 and June 2010 might have to be repeated or confirmed. However, the FDA has not made any allegations of fraud.

In the Cetero bankruptcy filing, filed in Delaware on March 26, the company claimed the FDA warning letter caused its “liquidity position to become severely constrained,” and some lenders stipulated the misconduct discovery was an event of default due to “apparent violation of applicable health laws and regulations,” according to Reuters. Cetero is using the Chapter 11 process to maximize recovery for these lenders, having reached a deal to sell the majority of the company’s assets in a credit bid. To aid in this process, Cetero has gained $15 million in debtor-in-possession financing to provide working capital.

Cetero’s listed estimated assets range from $1 million to $10 million. The company has a $11 million 2012 revenue to date and roughly $248 million in liabilities, according to the court filing.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing